WHY 1070 nm BEST WAVELENGTH TO TREAT PARKINSON'S, ALZHEIMER'S, ACQUIRED BRAIN INJURY, AND COVID FOG

In this video interview, neuropsychophysiologist and QuietMIND FOUNDATION founder Dr Marvin Berman discusses the latest findings with the Neuradiant 1070 photobiomodulation helmet and why 1070 nanometre appears to be the optimum wavelength for using light therapy to treat neurodegenerative diseases such as Parkinson's and Alzheimer's; acquired brain injuries; autism and even long COVID brain fog.

He talks about how outcomes are even better when the helmet is used in conjunction with individualised EEG brainwave-led neurobiofeedback, and answers viewer's questions such as does hair block light therapy and how the Neuradiant 1070 helmet compares to Vielight.

The Neuradiant 1070 represents the next generation photobiomodulation technology by being the first of its kind to deliver 1070 nanometre infrared light therapy to the brain in combination with the 4-quadrant control that enables clinicians to control the pulse in certain quadrants of the brain.

You can read the results of a clinical trial showing that 1070 nanometre light therapy was successful in improving cognition in patients with dementia here: http://www.aginganddisease.org/EN/10.14336/AD.2021.0229

You can find the study showing how the Neuradiant 1070 improved long COVID brain fog here: https://pubmed.ncbi.nlm.nih.gov/37018063/#:~:text=Each%20device%20for%20PBM%20delivery,treat%20long%20COVID%20brain%20fog.

To find out more about upcoming clinical trials visit the QuietMIND Foundation website, clinical trials tab: https://www.quietmindfdn.org/trials.html

Read independent reviews from people who have used the Neuradiant 1070 photobiomodulation helmet:

https://au.trustpilot.com/review/neuronic.online

For a five per cent discount off the Neuradiant 1070 photobiomodulation helmet retail price please use this link: https://neuronic.online/discount/SuviM5

Did you know Neuronic devotes 100 per cent of profits to advance the science and development of photobiomodulation through an ongoing program of basic science and applied clinical trials.

Follow our journey!
https://direct.me/suvisjournalism